SEC Form 4 · accession 0001193125-26-294692
Fulcrum Therapeutics, Inc. · FULC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kate Haviland
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001680581
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.66 | Jun 30, 2026 | A | 32,000 | A | — | Jun 29, 2036 | Common Stock | 32,000 | 32,000 | D |
Explanation of responses
- F1This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.